Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Mild to Moderate Asthma
Phase PHASE1
Enrollment 12
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CDX-622 — Administered Intravenously

Primary Outcomes

  • To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma. (Day 1 up to Day 85 (12 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Celldex Therapeutics
Contact Information
Study Contact:
Celldex Therapeutics
844-723-9363
clinicaltrials@celldex.com
Mariana Mosqueda
Mariana.Mosqueda@ucsf.edu
University of California, San Francisco
Christine Nguyen
Christine.Nguyen@ucsf.edu
University of California, San Francisco
Interventions
  • Drug: CDX-622 — Administered Intravenously
Study Locations (4 sites)
University of California, San Francisco, San Francisco, California 94143 United States
The University of Kansas Medical Center, Kansas City, Kansas 66160 United States
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Key Inclusion Criteria: 1. Males and females, ≥ 18 years of age 2. Diagnosis of mild to moderate asthma for at least 12 months 3. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal 4. Airway reversibility ≥ 12% and 200 mL improvement in FEV1 5. Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment 6. Willing and able to comply with all study requirements and procedures Key Exclusion Criteria: 1. Females who are pregnant or nursing 2. Pulmonary disease other than asthma 3. Systemic diseases with elevated eosinophils other than asthma 4. Hospitalization for treatment of asthma in the past 12 months or required oral corticosteroids due to asthma within the past 6 months 5. History of needing ventilator support due to asthma 6. Current nasal polyps 7. Severe or uncontrolled asthma 8. History of smoking or vaping within the past 6 months 9. Tuberculosis, hepatitis B or C virus, or HIV 10. Immunomodulating biologic therapies within the past 3 months for non-extended half-life biologics. 11. Prior receipt of TSLP or KIT inhibitors such as tezepelumab or briquilimab Additional protocol defined inclusion and exclusion criteria could apply.
Conditions Depression - Major Depressive Disorder, ...
Phase PHASE4
Enrollment 27
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments. This study will investigate two alternative treatment options for people whose depression has not responded to standard treatments: repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, and ketamine, a fast-acting medication. It can be difficult to decide between these interventions in clinical practice, and selecting between them often comes down to patient preference and trial and error. This study is working to optimize the selection approach: using biological and behavioral markers to match each person to identify biomarkers that may predict response to rTMS or ketamine. Investigators believe that differences in how individuals respond to rTMS versus ketamine are partly explained by differences in how their brains are organized, and that these differences can be measured and used to guide intervention decisions. This is an early-stage pilot study designed to test whether this biomarker-based approach is practical and acceptable to patients. Investigators will evaluate how well a combination of brain imaging and clinical data can predict, at the individual level, who is likely to respond to rTMS versus ketamine. The ultimate goal is to develop a reliable, scalable tool that helps clinicians make faster and more informed intervention decisions, reducing the time people with treatment-resistant depression spend searching for an antidepressant that works.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: TMS — rTMS will be administered as intermittent theta burst simulation (iTBS) delivered to the left dorsolateral prefrontal cortex with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly rTMS sessions).
  • Drug: Ketamine — Ketamine is a dissociative anesthetic with rapid-acting antidepressant properties. It will be administered in 6 total sessions (3 days x 2 weeks), each comprising a single subanesthetic dose of ketamine (0.5 mg/kg) delivered intravenously over 40 minutes.

Primary Outcomes

  • Change from Baseline to 2-Week Post-Intervention Score in Hamilton Depression Rating Scale (HDRS) Score (Baseline to 2-weeks post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-10
Completion: 2028-12
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 27 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: Icahn School of Medicine at Mount Sinai, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Conor Liston, MD, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Research Coordinator, Interventional Psychiatry Program
646-962-2900
tmsinfo@med.cornell.edu
Research Coordinator, Interventional Psychiatry Program
646-962-2900
tmsinfo@med.cornell.edu
Weill Cornell Medicine
Conor Liston, MD, PhD
Weill Cornell Medicine
Interventions
  • Device: TMS — rTMS will be administered as intermittent theta burst simulation (iTBS) delivered to the left dorsolateral prefrontal cortex with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly rTMS sessions).
  • Drug: Ketamine — Ketamine is a dissociative anesthetic with rapid-acting antidepressant properties. It will be administered in 6 total sessions (3 days x 2 weeks), each comprising a single subanesthetic dose of ketamine (0.5 mg/kg) delivered intravenously over 40 minutes.
Study Locations (1 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Adults of all genders aged 18-70 at the time of screening 3. Diagnosis of Major Depressive Disorder (by DSM-5 criteria) 4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \>= 14 or as determined by a study clinician) 5. Failed at least 1 prior trial of standard first-line treatment for MDD per the modified Antidepressant Treatment History form, the Maudsley Staging Method, and APA Practice Guidelines (e.g., SSRI, SNRI, CBT) OR initiated and discontinued a trial of a first-line treatment for MDD (e.g. could not tolerate side effects, etc.) 6. Not currently taking antidepressants OR on a stable dose of antidepressant for at least 1month prior to screening and plans to remain off antidepressants OR on this stable dose for the duration of participation 7. Current medication regimen is compatible with safe participation in the trial in the assessment of a study clinician 8. Access to psychiatric care before, during, and after completion of the study 9. For females of reproductive potential: agreement to use effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation 10. Proficiency in English sufficient to complete assessments and follow study procedure instructions 11. Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: 1. Imminent risk of suicide 2. Presence of primary psychiatric diagnosis other than MDD (e.g., post-traumatic stress disorder, obsessive-compulsive disorder, MDD with psychotic features, primary psychotic illness, bipolar I or II disorder) 3. History of epilepsy or a history of seizures that would influence the participant's risk for TMS-evoked seizures; history of any condition / concurrent medication that could notably lower seizure threshold in the estimation of a study clinician 4. Met criteria for any clinically significant substance use disorder (by DSM-V criteria) with active substance misuse in the 6 months prior to screening 5. Lifetime history of PCP/ketamine abuse 6. History or presence of significant neurological disorder that may be contributing to current depressive symptoms in the judgment of a study clinician (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy) 7. Presence of medical contraindications to ketamine, including liver function tests \> 2.5x normal limit, recent myocardial infarction, congestive heart failure \> stage 2, angina pectoris, clinically significant bradycardia or tachycardia at the baseline assessment, or uncontrolled hypertension 8. MRI contraindication, including presence of ferromagnetic foreign metal bodies or implants, implanted or conductive ferromagnetic objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), and ferromagnetic permanent make-up that may undergo heating in an MRI scanner 9. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation 10. Abnormal bloodwork that may be contributing to depressive symptoms in the estimation of a study clinician (e.g. indicators of clinically significant hypothyroidism, kidney failure, liver failure, etc.) 11. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures
Conditions Treatment Resistant Depression
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Background: 30-50% of patients with Major Depressive Disorder (MDD) do not respond adequately despite two or more antidepressant treatments with proper dosage and timing of administration, configuring a condition of Treatment-Resistant Depression (TRD). Repetitive Transcranial Magnetic Stimulation (rTMS) is a neuromodulation technique that uses a magnetic field to stimulate focal cortical brain regions and it has been approved by the FDA for the treatment of TRD. Accelerated rTMS (arTMS) protocols involve multiple daily sessions of rTMS and they have been shown to be equally effective and safe compared to rTMS protocols, with reduced administration time and potentially faster antidepressant efficacy. Objectives: The main aim of this study is to identify MDD endophenotypes/biotypes predictive of response to accelerated treatment of rTMS to better characterize the clinical correlates of response in patients with TRD. Eligibility: Subjects between 18 and 65 years suffering from TRD in stable psychopharmacological treatment for at least one month. Design: This clinical trial includes three phases: 1) a screening phase; a rTMS continued treatment phase; and a follow-up. In order to be enrolled, participants will be screened with: * Medical history to assess the existence of the inclusion criteria and exclude any medical conditions that could contraindicate treatment with arTMS * Questionnaires After being enrolled, baseline data will be collected. In particular, participants will be administered: * Questionnaires * Functional MRI * Cognitive tasks * Eye examination with Electroretinography (ERG) * Blood sampling * Salivary cortisol sampling Repetitive TMS will be delivered during 5 outpatient treatment days (4 times/die). After treatment patients will be contacted by telephone on a weekly basis for the first 3 weeks, to carry out an assessment of the clinical condition. A follow-up visit, in the clinic, will be carried out after 21 days from the last stimulation (Friday), with the administration of psychometric scales. Blood samples will be taken on the first day of stimulation and the day after the last stimulation. Salivary cortisol sampling will be taken before the start of the stimulation protocol, after the first stimulation day and immediately after the last stimulation session foreseen by the protocol. fMRI will be performed during baseline and at the end of treatment. ERG will be performed before the start of the stimulation protocol, after the first stimulation and immediately after the last stimulation session foreseen by the protocol. Patients will undergo ERG again during the follow-up visit at 21 days. Treatment includes: * rTMS: A brief electrical current passes through the coil placed on the head. At each day, participants will receive four rTMS sessions (36 min), with a 55 min interval between sessions. * MRIs: Patients will undergo two MRI sessions lasting 45 min. Blood pressure and respiratory rate will be recorded…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Accelerated Repetitive Transcranial Magnetic Stimulation — rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).

Primary Outcomes

  • Changes in psychometric test indicator of depression - MADRS (Baseline; each 1 day of treatment ; at 1, 2, 3 and 4 weeks.)
  • Changes in psychometric test indicator of depression - HAM-D 21 (Baseline; 1 week; 4 weeks)
  • Changes in neuroplasticity - structural RM and fMRI (physiological parameter) (Baseline; day 6)
  • Changes in neuroplasticity - DTI (physiological parameter) (Baseline; day 6)
  • Changes in responsivity of nervous tissue (physiological parameter) (Baseline; 4 weeks)
  • Rate of genetic polymorphism predictor of treatment response (Baseline; day 6)
  • Change in BDNF level (physiological parameter) (Baseline; day 6)
  • Change in pro-BDNF (physiological parameter) (Baseline; day 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-28
Completion: 2028-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ITAB - Institute for Advanced Biomedical Technologies
Contact Information
Study Contact:
Mauro Pettorruso, MD, PhD
+393391979487
mauro.pettorruso@unich.it
Mauro Pettorruso, MD, PhD
+393391979487
mauro.pettorruso@unich.it
ITAB
Interventions
  • Device: Accelerated Repetitive Transcranial Magnetic Stimulation — rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
Study Locations (1 sites)
ITAB, Chieti, 66100 Italy
Eligibility Criteria
Inclusion Criteria: * Current diagnosis of Major Depressive Disorder (MDD), based on the Diagnostic and Statistical Manual of Mental Disorder - Fifth Edition (DSM-5); * Subjects without clinical response to at least two antidepressant treatments administered at adequate dosage and duration during the current episode; * Stable psychopharmacological treatment for at least one month. Exclusion Criteria: * Co-morbidity with organic diseases that could interfere with magnetic stimulation safety (epilepsy, brain lesions or diseases, previous neurosurgery, metal grafts, cardiac devices) based on applied procedure guidelines; * Diagnosis of Substance or Alcohol Use Disorder (DSM-5) in the past 6 months; * Substances of abuse or alcohol acute intoxication or abstinence; * Co-morbidity with significant organic or neurological diseases; * Personal or familiar (1st degree relatives) medical history of seizures; * Significant eye diseases that could interfere with ERG execution; * For female patients: Pregnancy/breastfeeding.

Skills for Wellness

NCT01980147
Recruiting
Conditions Schizophrenia, Bipolar Disorder, Major D...
Phase NA
Enrollment 360
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Severe mental illness such as schizophrenia and mood disorders typically develops at a young age and can cause life-long disability. Currently available treatments cannot cure severe mental illness. This makes it important to find ways to prevent severe mental illness in young people before it has a chance to develop. This research study will pilot a new preventive intervention for young people who are at high risk of developing severe mental illness. The investigators will target early preceding factors (the 'antecedents') to severe mental illness which includes anxiety, unusual hearing and visual experiences, the loss of previously acquired abilities, and sudden and unpredictable changes in mood. These antecedents strongly predict an increased risk of developing severe mental illness. They are often impairing and distressing to the individual but can be improved with self-management skills and parent training, and they are present in the individual years before the onset of severe mental illness which makes them an ideal target for early intervention. The goal is to intervene early enough in the young person's life that severe mental illness can be prevented, hopefully leading to a happy, healthy and productive adulthood. The investigators want to test the acceptability and short-term efficacy of this new preventive intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: maCBT — Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.

Primary Outcomes

  • Early antecedents to severe mental illness (4-6 months after the end of the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2014-03-22
Completion: 2028-06-30
Eligibility
Age: 9 Years – 21 Years
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nova Scotia Health Authority
Collaborators: Nova Scotia Health Research Foundation, Canadian Institutes of Health Research (CIHR)
Principal Investigators:
  • Rudolf Uher, MD PhD (PRINCIPAL_INVESTIGATOR) - Nova Scotia Health Authority
Contact Information
Study Contact:
Rudolf Uher, MD PhD
uher@dal.ca
Nova Scotia Health Authority
Jill Cumby, RN
jill.cumby@nshealth.ca
Nova Scotia Health Authority
Interventions
  • Behavioral: maCBT — Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
Study Locations (2 sites)
Nova Scotia Health Authority, Halifax, Nova Scotia B3H 2E2 Canada
Nova Scotia Health Authority, Halifax, Nova Scotia B3H 2E2 Canada
Eligibility Criteria
Inclusion Criteria: * FORBOW (Families Overcoming Risks and Building Opportunities for Well-Being) participant between 9-21 years old * Meet criteria for one or more antecedents (psychotic like experience, basic symptoms, anxiety or affective lability) Exclusion Criteria: * Diagnosis of severe mental illness (schizophrenia, other psychotic disorder, bipolar disorder, severe major depressive disorder) * More than 3 sessions of structured psychological therapy in the past 12 months * Insufficient understanding of the English language to benefit from the intervention
Conditions Breast Cancer Female NOS, General Anxiet...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate whether psychological status affects the response to neoadjuvant immunotherapy in triple-negative breast cancer (TNBC) and how it relates to immune changes during treatment. Participants will receive standard therapy, undergo psychological assessments, and provide blood and saliva samples for biomarker testing. By linking psychological status with immune profiles and treatment outcomes, the study seeks to clarify how mental state may influence immunotherapy effectiveness.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Pathological Complete Response (pCR) Rate (At the time of definitive surgery)
  • Event-Free Survival (EFS) (18 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-01
Completion: 2027-06-30
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhi-Ming Shao
+86-021-64175590
zhimin_shao@yeah.net
Zhi-Ming Shao
+86-021-64175590
zhimin_shao@yeah.net
Fudan University Shangahi Cancer Center
Interventions
N/A
Study Locations (1 sites)
Fudan University Shangahi Cancer Center, Shanghai, Please Select 20080 China
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria: 1. Age ≥ 18 years; 2. Female patients; 3. Voluntarily agrees to participate in the study and signs the informed consent form, with good compliance and willingness to complete follow-up assessments; 4. Histologically confirmed invasive triple-negative breast cancer (TNBC), defined as ER \< 1%, PR \< 1%, and HER-2 0-1+ by IHC, or HER-2 2+ with negative FISH/CISH results (no gene amplification); 5. Planned to receive neoadjuvant immunotherapy-based treatment as part of routine clinical care. Exclusion Criteria Patients will be excluded if any of the following conditions apply: 1. Presence of distant metastasis; 2. History of other malignancies, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or cancers with no evidence of disease for ≥ 5 years; 3. Participation in another clinical trial and receipt of an investigational drug or treatment within 30 days before initiation of neoadjuvant therapy; 4. Known immunodeficiency or HIV infection; 5. Severe cardiac, pulmonary, hepatic, or renal dysfunction; 6. Uncontrolled infection or active systemic infection; 7. Pregnancy or breastfeeding; 8. Severe psychological or cognitive impairment that precludes completion of psychological assessments.
Conditions Insomnia
Phase NA
Enrollment 275
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this randomized controlled clinical trial is to assess a novel cognitive-behavioral program for sleep and mental health using a multidomain web platform (eCBTi+) in participants with insomnia and subjective cognitive complaint. The main questions it aims to answer are: * Whether the eCBTi+ intervention improves sleep (subjective: Insomnia severity index \[ISI\], objective: EEG-based sleep efficiency) sleep and mental health (Geriatric Anxiety Index \[GAI\] and Geriatric Depression Scale \[GDS\]) compared to the control intervention * Whether the eCBTi+ intervention improves cognitive abilities (subjective: Cognitive Failure Questionnaire \[CFQ\], objective: CANTAB executive functions composite score) compared to the control intervention

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: cognitive behavioral therapy for sleep, anxiety, and depression — This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
  • Behavioral: education about healthy nutrition habits and communication in older age — This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings

Primary Outcomes

  • Insomnia severity index (At baseline, at 10-12 weeks and at 24 weeks after the start of the intervention)
  • Subjective cognitive impairment based on cognitive failure questionnaire (At baseline, at 10-12 weeks and at 24 weeks after the start of the intervention)
  • Objective cognitive performance based on a composite score for executive functions from the CANTAB (At baseline and at 24 weeks after the start of the intervention)
  • Geriatric anxiety index (At baseline, at 10-12 weeks and at 24 weeks after the start of the intervention)
  • Geriatric depression scale (At baseline, at 10-12 weeks and at 24 weeks after the start of the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-15
Completion: 2026-12
Eligibility
Age: 60 Years – 99 Years
Sex: ALL
Volunteers: true
Enrollment: 275 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Contact Information
Study Contact:
Thien Thanh Dang-Vu, MD PhD
+1 (514) 340-3540
tt.dangvu@concordia.ca
Rebecca Robillard, PhD
+1 (613) 722-6521
rebecca.robillard@uottawa.ca
Rébecca Robillard, PhD
+1 613-722-6521
e-cosmos@uottawa.ca
The Royal's Institute of Mental Health Research (IMHR)
Interventions
  • Behavioral: cognitive behavioral therapy for sleep, anxiety, and depression — This intervention addresses insomnia, anxiety and depression via modules covering all the core CBTi components: psychoeducation about insomnia, relaxation, cognitive restructuring, stimulus control, sleep restriction and stress management; as well as psychoeducation about anxiety and low mood, behavioral activation strategies, and strategies to better manage ruminations. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings.
  • Behavioral: education about healthy nutrition habits and communication in older age — This intervention addresses healthy nutrition habits as well as communication and aging. The modules are adapted to older adults and include short texts, pictures, quizzes with feedback, interactive exercises, logbooks, audio and video recordings
Study Locations (2 sites)
The Royal's Institute of Mental Health Research (IMHR), Ottawa, Ontario K1Z7K4 Canada
Centre intégré universitaire de santé et de services sociaux du Centre-Sud-de l'Île-de-Montréal. CCSMTL - IUGM, Montreal, Quebec H3W 1W5 Canada
Eligibility Criteria
Inclusion * age 60 years or older at the time of enrolment * Sleep Condition Indicator, SCI ≤ 16 and/or meeting DSM-V criteria based on the symptoms assessed by the SCI * subjective cognitive complaints (self-report version of Everyday Cognition scale (ECog), score ≥ 2 on any item) * ability to read and understand French or English * ability to use a smartphone or tablet, and access to home internet connection * If on hypnotic or psychotropic medication (including cannabis), being on stable dosage for at least 2 months prior to study entry * Score on the STOP-BANG questionnaire \< 3 corresponding to participants with low risk of obstructive sleep apnea Exclusion * located outside of Québec or Ontario * current hospitalization or planned major surgery * uncorrected severe hearing or vision impairment * reported diagnosis of major neurocognitive disorder or mild cognitive impairment (MCI) * performance suggestive of major neurocognitive disorder or MCI on T-MoCA \< 17 * reported diagnosis of schizophrenia or bipolar disorder * reported diagnosis or positive screen on the MINI for psychotic or bipolar disorders * high suicidal risk, as assessed by the modified Columbia-Suicide Severity Rating Scale * reported diagnosis or positive screening (apnea-hypopnea index \>30 on a level 3 home sleep apnea test) for another untreated sleep disorder (e.g., sleep disordered breathing (OSA), REM sleep behavior disorder (RBD), restless legs syndrome (RLS); individuals with treated and controlled OSA (residual apnea-hypopnea index \<30 and good therapeutic compliance) or RLS will not be excluded * current shift work * currently receiving CBT, having received CBTi in the past * frequent alcohol consumption having an impact on functionning (\>10 glasses/week and having a significant impact on functionning) * illicit drugs use (more than once a month) Additional exclusion criteria for neuroimaging * psychotropic (including hypnotic) medication in the past 2 weeks * contraindications for MRI (e.g., pacemaker, metallic implant, claustrophobia) * unable or unwilling to come to one of the participating MRI centers (Montreal, Ottawa) * medical conditions likely to affect sleep; in particular: * current neurological disorder (e.g., epilepsy with any seizure in the past year, concussion in the past 3 months, multiple sclerosis, Parkinson's disease) * past history of brain lesion (e.g., brain hemorrhage, brain tumor, any condition having required brain surgery) * major surgery (i.e., requiring general anesthesia) in the past 3 months * untreated thyroid disorder * chronic pain syndrome self-reported as interfering with sleep (e.g., migraine, fibromyalgia, rheumatoid arthritis) * recent and severe infection in the past 3 months (e.g., pneumonia, kidney infection) * active cancer or treated cancer with post-cancer treatment for less than 2 years Inclusion/exclusion criteria for good sleepers Twenty-five good sleepers without cognitive complaint will be recruited as controls for the MRI session following the same criteria described above, except that SCI ≥ 17, not meeting the diagnostic criteria for chronic insomnia as assessed by the insomnia module of the SCID and no subjective cognitive complaint.
Conditions Schizophrenia and Related Disorders
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia. Schizophrenia patients with depressive symptoms will be exposed to rTMS to improve their symptoms.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Active rTMS stimulation — Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
  • Device: Sham rTMS stimulation — Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.

Primary Outcomes

  • Brain connectivity as indicated by resting-state functional connectivity (rsFC) values as assessed by functional MRI (fMRI) (baseline, visit 11 (about 2 week after baseline), visit 21 (about 4 weeks after baseline))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-23
Completion: 2030-06-01
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center, Houston
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Xiaoming Du, PhD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center, Houston
Contact Information
Study Contact:
Alina Siatka
713-486-2740
Alina.Siatka@uth.tmc.edu
Xiaoming Du, PhD
443-882-9717
Xiaoming.Du@uth.tmc.edu
Xiaoming Du, PhD
713-486-2700
Xiaoming.Du@uth.tmc.edu
The University of Texas Health Science Center at Houston
Interventions
  • Device: Active rTMS stimulation — Active H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
  • Device: Sham rTMS stimulation — Sham H-coil delivered rTMS sessions will be given three times per treatment visit for up to 20 visits for about 4 weeks. There are about 30 minutes breaks between adjacent TMS sessions. Each TMS session takes about 3 to 4 minutes to complete.
Study Locations (1 sites)
The University of Texas Health Science Center at Houston, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Male and female ages between ages 18-60 years. * Ability to give written informed consent (age 18 or above). * Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above 10. * Score of Calgary depression scale for schizophrenia (CDSS) ≥ 3. Exclusion Criteria: * Inability to sign informed consent. * Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but are not limited to: stroke, repeated seizure, history of significant head trauma with cognitive sequela, CNS infection or tumor, other significant brain neurological conditions. * Significant alcohol or other drug use other than nicotine or marijuana dependence. * Inability to refrain from using alcohol and/or marijuana 24 hours or more prior to experiments. * Pregnancy, as classified by a woman of child-bearing potential who is not using a contraceptive and has missed a menstrual period; or by self-report; or by positive urine pregnancy test. * For MRI, inability to participate in the MRI scanning due to metallic devices or objects (cardiac pacemaker or neurostimulator, some artificial joints, metal pins, surgical clips or other implanted metal parts) or declining to get in the scanner. * Failed TMS safety questionnaire.
Conditions Major Depression, Pregnancy, Postpartum ...
Phase NA
Enrollment 156
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, sham-controlled trial to determine whether treatment with transcranial direct current stimulation (tDCS) is superior to a sham condition at reducing the symptoms of depression in pregnant people with moderate to severe depression. The study aims to enrol 156 participants across all sites. Data collection occurs at baseline, immediately after treatment, every 4 weeks during pregnancy and 4-, 12-, 26- and 52-weeks postpartum

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: active tDCS — 2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
  • Other: workbook — Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
  • Device: sham tDCS — Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks

Primary Outcomes

  • Depressive symptoms post treatment (End of Week 3 of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-08
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Women's College Hospital
Collaborators: Centre for Addiction and Mental Health, Sunnybrook Health Sciences Centre
Principal Investigators:
  • Sophie Grigoriadis, MD, PhD (PRINCIPAL_INVESTIGATOR) - Sunnybrook Health Sciences Centre
  • Daniel Blumberger, MD, MSc (PRINCIPAL_INVESTIGATOR) - Centre for Addiction and Mental Health
  • Simone Vigod, MD, MSc (PRINCIPAL_INVESTIGATOR) - Women's College Hospital
Contact Information
Study Contact:
Simone Vigod
4163236400
simone.vigod@wchospital.ca
Sophie Grigoriadis, MD
416-480-5677
sophie.grigoriadis@sunnybrook.ca
Sunnybrook Health Sciences Centre
Sophie Grigoriadis, MD
Sunnybrook Health Sciences Centre
Interventions
  • Device: active tDCS — 2mA of direct current delivered in 15 sessions lasting 30 minutes each over 3 weeks
  • Other: workbook — Self-directed depression in pregnancy workbook completed during each session to control the in-session brain state
  • Device: sham tDCS — Sham stimulation in which the current turns off after 30 seconds in a slow ramp down that mirrors sensory adaptation in ongoing stimulation, delivered in 15 sessions lasting 30 minutes each over 3 weeks
Study Locations (2 sites)
Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5 Canada
Women's College Hospital, Toronto, Ontario M5S1B2 Canada
Eligibility Criteria
Inclusion criteria: 1. Adult, ≥18 years of age 2. Singleton pregnancy, 12 to end of 32 weeks single gestation at randomization 3. In a major depressive episode (MDE) with at least moderate symptom severity (PHQ-9 ≥10 and confirmed using MINI International Neuropsychiatric Interview as MDE without psychotic features) 4. Assessed by a psychiatrist at one of the study recruitment sites during pregnancy, and offered the option of antidepressant medication for treatment but declined to use 5. No new treatments for depression (i.e. psychological or somatic) and no pharmacological treatment for depression in the 4 weeks prior to starting treatment Exclusion criteria: 1. Active alcohol or substance use disorder in previous 12 months as assessed by GAIN-SS 2. Active suicidality as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) 3. Bipolar disorder as assessed by MINI International Neuropsychiatric Interview 4. Schizophrenia or other psychotic disorder as assessed by MINI International Neuropsychiatric Interview 5. Major unstable or life-threatening medical illness (e.g. such as advanced cancer), pre-eclampsia/eclampsia in current pregnancy or neurologic illness or seizure history 6. Major congenital anomalies or major obstetrical complications in current pregnancy (determined by clinical PI/Co-I assessment) 7. Metal implants in cranium or any electrical implants 8. Benzodiazepine (except intermittent low-dose lorazepam no more than 2mg equivalent per day) or anticonvulsant use as these interfere with anodal tDCS 9. Visibly non-intact skin/rash on scalp areas at stimulation electrode sites 10. Unable to consent or complete study measures in English, or unable to complete depression in pregnancy workbook (the attention-control) in French or English
Conditions Glucose Metabolism Disorders (Including ...
Phase Not Applicable
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study examines the association of variability in glucose values over a 10-day period with cognitive function and functional status among individuals with prediabetes, aged 50 or older.

Design

Study type: Observational Observational model: Ecologic Or Community Time perspective: Cross Sectional

Interventions / Regimen

  • Device: Continuous Glucose Monitoring System (CGMS) — Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.

Primary Outcomes

  • Aggregate Executive Functioning Score (Day 10)
  • Aggregate Memory Score (Day 10)
  • Aggregate Language Score (Day 10)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-03-01
Completion: 2026-12-31
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Maryland, Baltimore
Collaborators: Baltimore VA Medical Center, University of Maryland, Baltimore County
Principal Investigators:
  • Tasneem Khambaty, PhD (PRINCIPAL_INVESTIGATOR) - University of Maryland, Baltimore County
Contact Information
Study Contact:
Kathleen Simpson
4106057179
Kathleen.Simpson@va.gov
Ashley Splain, BA
asplain1@umbc.edu
Tasneem Khambaty, PhD
410-455-2304
khambaty@umbc.edu
Baltimore VA Geriatric Research Education and Clinical Center (GRECC)
Interventions
  • Device: Continuous Glucose Monitoring System (CGMS) — Continuous Glucose Monitoring System (CGMS)- minimally invasive sensors that measure glucose concentrations at 5-min intervals over several days.
Study Locations (1 sites)
Baltimore VA Geriatric Research Education and Clinical Center (GRECC), Baltimore, Maryland 21201 United States
Eligibility Criteria
Inclusion Criteria: * Aged 50 years and older * At least 8th grade education Exclusion Criteria: * Diagnosed type 1 or type 2 diabetes * Current use of mediation for diabetes (oral hypoglycemic agents, insulin), or with diabetic properties (e.g., steroids) * Chronic disorders (cardiovascular disease, peripheral vascular disease, stroke, transient ischemic attack, chronic kidney disease, past year cancer) * Neurological disorders (e.g., Parkinson's, epilepsy, multiple sclerosis) * History of dementia or suspected dementia * Known HIV * Serious mental illness, psychosis, or use of psychotropic medication * Heavy alcohol use
Conditions Positive Affect, Depression
Phase PHASE2
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare the effects of Virtual Reality-Reward Training (VR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Virtual Reality-Reward Training (VR-RT) — Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
  • Behavioral: Virtual Reality-Memory Training (VR-MT) — Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral non-personal stories

Primary Outcomes

  • The Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Subscale (MASQ-AD) (Change from Week 0 assessment to Post-Assessment (Week 8). Change from Week 0 assessment to Follow-Up (Week 12).)
  • Positive Valence Systems Scale (PVSS-21) (Change from Week 0 assessment to Post-Assessment (Week 8). Change from Week 0 assessment to Follow-Up (Week 12).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-08
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Contact Information
Study Contact:
Aleeza West
‪(323) 508-3571‬
vrtrainingucla@proton.me
University of California, Los Angeles
Michelle Craske, PhD
University of California, Los Angeles
Interventions
  • Behavioral: Virtual Reality-Reward Training (VR-RT) — Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.
  • Behavioral: Virtual Reality-Memory Training (VR-MT) — Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral non-personal stories
Study Locations (1 sites)
University of California, Los Angeles, Los Angeles, California 90095 United States
Eligibility Criteria
Inclusion Criteria: 1. At least 18 years old 2. Fluent in written and spoken English 3. Meet all of the following dimensional score cutoffs: 1. Score on the DASS-21 depression subscale must be ≥ 8 2. Score on the PANAS-P of 27 or lower 3. Score on the WSAS of ≥ 11 Exclusion Criteria: 1. Lifetime history of bipolar disorder, psychosis, mental retardation, or organic brain damage 2. Substance use disorder in the past 6 months 3. Current use of psychotropic medications 4. Currently pregnant or planning to become pregnant 5. Self-reported frequent motion sickness 6. Self-reported seizures within the last year and/or a diagnosis of epilepsy
Conditions Depression, Obsessive-Compulsive Disorde...
Phase Not Applicable
Enrollment 156000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

In this study, real-world data will be used to better understand the effects patient characteristics, symptoms and TMS protocol parameters have on clinical outcomes with NeuroStar TMS.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Device: NeuroStar Advanced TMS Therapy System — non-invasive brain stimulation device

Primary Outcomes

  • Change in clinical assessment score from baseline to post-treatment (8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-25
Completion: 2035-12
Eligibility
Age: 5 Years – 120 Years
Sex: ALL
Volunteers: false
Enrollment: 156000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Neuronetics
Principal Investigators:
  • Eleanor Cole, PhD (STUDY_DIRECTOR) - Neuronetics
Contact Information
Study Contact:
Neha Goyal
763-528-1599
neha.goyal@neurostar.com
Eleanor Cole, PhD
415-724-7960
Eleanor.cole@neurostar.com
Eleanor Cole
Neuronetics
Interventions
  • Device: NeuroStar Advanced TMS Therapy System — non-invasive brain stimulation device
Study Locations (1 sites)
Neuronetics, Malvern, Pennsylvania 19355 United States
Eligibility Criteria
Inclusion Criteria: * Male or female reported in database and not an invalid entry * Age reported and not an invalid entry * Treatment date of November 01, 2008 or later. Exclusion Criteria: • Incomplete information on treatment parameters
Conditions Intracerebral Hemorrhage, Stroke, Hypert...
Phase Not Applicable
Enrollment 1018
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The aim is to compare the rate of hypertensive subjects with ICH who reach SBP target with stability within 60 minutes of enrollment, among patients treated with IV clevidipine with those treated with alternate IV antihypertensive regimen.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Clevidipine Injection — Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
  • Drug: Alternate IV Antihypertensive Regimen — The alternate IV antihypertensive regimen would be the institutional standard management at designated "non-clevidipine hospitals". It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.

Primary Outcomes

  • Blood Pressure Monitoring (15 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-01
Completion: 2028-07-30
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 1018 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zeenat Qureshi Stroke Institute
Collaborators: Chiesi USA, Inc.
Contact Information
Study Contact:
Jeein Kim
(949) 824-5011
pashmeen.lakhani@zqsi.org
University of California
Sean R. McDougall
University of California
Melody Halio
661-949-5000
pashmeen.lakhani@zqsi.org
Antelope Valley Medical Center
Interventions
  • Drug: Clevidipine Injection — Sites will be trained and instructed to administer IV clevidipine according to Food and Drug Administration label, which recommends starting at 1-2 mg/hour, and then doubling the dose initially at short (90 second) intervals. As the BP approaches the goal, the increase in doses should be less than doubling and the time between dose adjustments should be lengthened to every 5-10 minutes. The desired therapeutic response for most patients occurs at doses of 4-6 mg/hour. Most patients have been treated with maximum doses of 16 mg/hour or less. There is limited short-term experience with doses up to 32 mg/hour, and because of lipid load restrictions, no more than 1000 mL or an average of 21 mg/hour of Clevidipine infusion is recommended per 24-hour period. There is little experience beyond 72 hours at any dose.
  • Drug: Alternate IV Antihypertensive Regimen — The alternate IV antihypertensive regimen would be the institutional standard management at designated "non-clevidipine hospitals". It is expected that most of these sites will be using IV nicardipine, which if administered per FDA label is started at 5 mg/hour and increased by 2.5 mg/hour every 5-15 minutes to a maximum dose of 15mg/hour, until desired BP is reached. Once the goal is reached, then the dose may be reduced to 3 mg/hour.
Study Locations (20 sites)
University of California, Irvine, California 92696-7600 United States
Antelope Valley Medical Center, Lancaster, California 93534 United States
Stanford Medical Center (Stanford Health Care), Palo Alto, California 94304 United States
Cleveland Clinic Martin North Hospital, Stuart, Florida 34994 United States
University of South Florida, Tampa, Florida 33606 United States
Cleveland Clinic Florida, Weston, Florida 33331 United States
Augusta University-Neuroscience Center, Augusta, Georgia 30912 United States
Wellstar Kennestone Regional Medical Center, Marietta, Georgia 30060 United States
Community Hospital, Munster, Indiana 46321 United States
Frederick Memorial Hospital, Frederick, Maryland 21701 United States
Eligibility Criteria
Inclusion Criteria 1. Age 18 years or older and less than 100 years. 2. Onset of new neurological deficits within 12 hours at the time of enrollment and IV clevidipine or alternate IV antihypertensive regimen can be initiated within 12 hours of symptom onset. 3. Clinical signs consistent with the diagnosis of stroke, including impairment of language, motor function, cognition, and/or gaze, vision, or neglect. 4. Initial National Institutes of Health Stroke Scale (NIHSS) score of 1 or greater. 5. Total GCS score (aggregate of verbal, eye, and motor response scores) of 5 or greater at enrollment 6. Computed Tomography (CT) scan of the brain demonstrates intraparenchymal hematoma with manual hematoma volume measurement \>5 cc (excluding microhemorrhages) 7. Admission SBP greater than and equal to 150 mmHg but less than 220 mmHg on two repeat measurements at least 5 minutes apart, but no more than 10 minutes apart. The reason for exclusion of ICH patients with initial SBP ≥220 mm Hg is based on a post hoc analysis of ATACH-2, which found that patients with initial SBP ≥220 mm Hg (22.8% of the cohort) reported higher rates of neurological deterioration at 24 hours and renal adverse events until day 7 or discharge in patients treated with intensive SBP reduction compared with standard SBP lowering, without any benefit in reducing hematoma expansion at 24 hours or death or severe disability at 90 days. 8. Signed and dated informed consent by subject, legally authorized representative, or surrogate before index hospital discharge for data collection and agreement to participate in 90- and 180-day follow-up visits. 9. Patients with anticoagulant-related ICH are eligible as long as anticoagulant reversal is concurrently undertaken consistent with AHA/ASA guidelines. 10. Patients who will undergo surgical evacuation consistent with AHA/ASA guidelines or local institutional guidelines are eligible unless surgical evacuation is being performed within 6 hours of initiation of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery will necessitate use of anesthetic agents which will confound the effect of IV clevidipine or alternate IV antihypertensive medication regimen. Ultra-early surgery/intervention was not used in the minimally invasive catheter evacuation followed by thrombolysis (MISTIE)/ Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage (CLEAR) trials, which required ICH patients to undergo a repeat CT scan after 6 hours to document absence of any hematoma expansion (with ≤5 mL hematoma growth) compared to a previous CT scan prior to any surgical intervention. 11. Patients requiring external ventricular drainage consistent with AHA/ASA guidelines or local institutional guidelines are eligible. Exclusion Criteria 1. Time of symptom onset cannot be reliably assessed. 2. Previously known neoplasms, arteriovenous malformation (AVM), or aneurysms. 3. Intracerebral hematoma considered to be related to trauma. 4. ICH located in infratentorial regions such as pons or midbrain (cerebellar ICH is not an exclusion criteria). 5. Subject considered a candidate for immediate surgical intervention by the neurosurgery service. 6. Pregnancy, parturition within previous 30 days, or active lactation. 7. Any history of bleeding diathesis or coagulopathy except anticoagulant related ICH. 8. Platelet count of less than 50,000/mm3. 9. Known sensitivity to nicardipine or clevidipine. 10. Patient's living will precludes aggressive ICU management. 11. Patients with allergies to soybeans, soy products, eggs, or egg products. 12. Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia. 13. Patients with severe aortic stenosis.